Dr. Andrew Teasdale

Senior Principal Scientist Impurity management and External Advocacy, AstraZeneca, UK

(via video call)

  • Leader of the IPEC EU ICH Q3D (Elemental Impurities) Implementation taskforce.
  • Chair of AstraZeneca’s Impurity Advisory Board
  • Inventor of the purge factor calculation concept used in the risk assessment of genotoxic impurities.
  • Chair of the Extractables and leachables safety information exchange (ELSIE) materials group and Joint Pharmaceutical Analytical Group (JPAG).
  • Leader of a number of industry expert groups for Pharmaceutical Research and Manufacturers of America (PhRMA), European Federation of Pharmaceutical Industries and Associations (EFPIA) and Product Quality Research Institute (PQRI)
  • Led the team developing the addendum to ICH M7 (Genotoxic Impurities) which provide definitive limits for common mutagenic reagents.
  • Editor of the first book specifically focused on the subject matter: Genotoxic Impurities: Strategies for Identification and Control.
  • Author of ICH Quality Guidelines: An Implementation Guide

Contact Us

Phone: +91 88490 97588

Email: contact@treffenmedia.com

Website: http://treffenmedia.com/


13 + 3 =